Search academic texts

Information × Registration Number 0215U003383, 0114U007236 , R & D reports Title Obtaining of recombinant analogue of heparin binding EGF-like growth factor in eukaryotic cells. popup.stage_title Head Kolybo Denys Volodymyrovych, Registration Date 28-01-2015 Organization A.V.Palladin Institute of Biochemistry of National Academy of Sciences popup.description2 Heparin binding EGF-like growth factor (HB-EGF) plays important role in most biological processes like cell migration, proliferation and differentiation. This factor also has a great significance in processes related to diphtheria toxin binding. Recombinant HB-EGF previously obtained in prokaryotic expression system stimulated cell proliferation, but effective concentration of recombinant protein was ten times higher than for native factor due to features of expression of eukaryotic recombinant proteins in prokaryotes. Production of recombinant HB-EGF in eukaryotes will significantly increase its biological activity owing to eukaryotic protein folding system and posttranslational modification system. Hence, recombinant HB-EGF produced in eukaryotes could be used for studying its biological functions and could be applied for developing drugs based on HB-EGF. Eukaryotic cells HEK293 expressing recombinant human heparin-binding growth factor were obtained by transfection with non viral transposon-mediated gene delivery system. Also, experiments in animal model shown the possibility of use transposon-based genetic constructs for treatment of various HB-EGF dependent pathological conditions in vivo. Product Description popup.authors Короткевич Н.В. Криніна О.І. Лабинцев А.Ю. Манойлов К.Ю. Олійник О.С. Сіромолот А.А. Чудіна Т.О. popup.nrat_date 2020-04-02 Close